Friday, March 16, 2012

Cost body backs Novartis MS pill in about-turn

A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in BaselLONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in the state health service after a change of heart by the country's healthcare cost-effectiveness watchdog. Friday's verdict from the National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently. ...


Courtesy of Yahoo News

No comments:

Post a Comment